Please find enclosed Un-audited Financial Results for QFY2027

67— GPT Healthcare Limited Erroeun| p Regd. Office: GPT CenJCt-25,r Secetor, Iil, Salt Lake, Kolkata —700 106, India CIN : L70101WB1989PLC047402 Phone : +91-33-4050-7000, Email : info@gptgroup.co.in, Visit us: www.gptgroup.co.in GPTHEALTH/CS/SE/2026-27 August 3, 2026 The Department of Corporate Services National Stock Exchange of India Limited BSE Limited, Exchange Plaza, Plot no. C/1, G Block, Phiroze Jeejeebhoy Towers, Bandra-Kurla Complex, Bandra (E), Dalal Street Mumbai - 400 051 Mumbai - 400001 Scrip Symbol: GPTHEALTH Scrip Code: 544131 ISIN: INE486R01017 Dear Sir/Madam Sub: Submission of Un-Audited Financial Results for the 1* quarter ended on June 30, 2026: In pursuance of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are to inform you that the Board of Directors at their meeting held today i.e. August 3, 2026, have inter-alia considered, approved and taken on record, the Un-Audited Financial Results of the Company for the 1%t quarter ended on June 30, 2026. A copy of Un-Audited Financial Results along with Limited Review Report of the Statutory Auditors thereon for the 1% quarter ended on June 30, 2026, as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, is enclosed herewith for your record and reference. Since the Company does not have any subsidiary / associate, there is no requirement for submitting Consolidated Financial Results for the 1** quarter ended on June 30, 2026. Kindly take the aforesaid information on record and oblige. Thanking You, Yours sincerely, For GPT Healthcare Limited Ankur Sharma Company Secretary and Compliance Officer M. No A31833 Encl. As Above. S.R. BatuiBoi & Co. LLP Sri Fioar ookt Chartered Accountants Kolkata - 700 016, India Tel : +91 33 6134 4000 Independent Auditor’s Review Report on the Quarterly and Year to Date Unaudited Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended Review Report to The Board of Directors GPT Healthcare Limited L. We have reviewed the accompanying statement of unaudited financial results of GPT Healthcare Limited (the “Company™) for the quarter ended June 30, 2026 (the “Statement”) attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the “Listing Regulations™). . The Company’s Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) “Interim Financial Reporting” prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company’s Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review. . We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, “Review of Interim Financial Information Performed by the Independent Auditor of the Entity” issued by the Institute of Chartered Accountants ofI ndia. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. . Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards (‘Ind AS’) specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement. For S.R. BATLIBOI & Co. LLP Chartered Accountants ICAI Firm-registration number: 301003E/E300005 per Sanjdy Kumar Agarwal Partner Membership No.: 060352 UDIN: L 60602352E CBDY T203) Place: Kolkata Date: August 3, 2026 5. Batliv& oCro. LLP, 3 Limited Liabilty Partnershwiitph LLP Identity No. AAB-4294 GPT HEALTHCARE LIMITED Registered Office: GPT Centre, JC-25, Sector - Ill, Salt Lake City, Kolkata - 700 106, India CIN : L70101WB1989PLC047402, Website: www.ilshospitals.com, Email : ghl.cosec@gptgroup.co.in Statement Of Unaudited Financial Results for the quarter ended June 30, 2026 (% i lakhs unless otherwise stated) Quarter Ended Year Ended y 30.06.2026 31.03.2026 30.06.2025 31.03.2026 Particulars , Auuddiittee d b Unaudited (Refer Note 4) Unaudited Audited 1 [Income. (a) Revenue from operations 12,620.43 12,637.18 10,710.86 47,254.70 (b) Other income 202,61 162.84 156.30 595.12 [Total income. 12,823.04 12,800.02 10,867.16 47,849.82 2 |Expenses (2) Cost of materials consumed 2,414.86 2,340.14 2,067.28 8,979.13 (b) Employee benefits expense 2,323.69 2,221.27 2,042.04 8,436.23 (c) Finance costs 216.27 218.18 163.28 824.04 (d) Depreciation and amortisation expense 688.09 694.91 618.16 2,708.83 (e) Other expenses 5,463.66 5,739.04 4,865.04 21,421.04 Total Expenses 11,106.57 11,213.54 9,755.80 42,369.27 3 |Profit before tax (1-2) 1,716.47 1,586.48 1,111.36 5,480.55 4 |Tax Expense () Current tax 471.00 480.00 199.00 1,258.00 (b) Deferred tax (27.67) (350.12) 144.18 36.62 () Adjustment of tax in respect of earlier year - - - (36.12) Total tax expenses 443.33 129.88 343.18 1,258.50 5 [Profit after tax (3-4) 1,273.14 1,456.60 768.18 4,222.05 6 |Other Comprehensive Income/ (Loss) (OCI) Items that will not be reclassified to profit or loss (1) Remeasurement of defined benefit plan (1.68) (13.21) (1.68)| (18.25) (ii) Income tax relating to above 0.42 3.84 0.49 5.31 Other Comprehensive Income/ (Loss) (1.26) 9.37) (1.19) (12.94) 7 |Total Comprehensive Income (5+6) 1,271.88 1,447.23 766.99 4,209.11 8 |Paid up equity share capital (face value of 10 each) 8,205.48 8,205.48 8,205.48 8,205.48 Other Equity 18,737.32 10 [Earnings per equity share (of £10 each) : (@) Basic () 1.55 1.78% 0.94* 5.15 (b) Diluted (%) 1.55" 1.78* 0.94* 5.15 The figures marked with () are not annualised Notes: 1. The above unaudited financial results of the Company for the quarter ended June 30, 2026 have been reviewed by the Audit Committee and thereafter approved by the Board of Directars at their respective meetings held on August 03, 2026. These unaudited financial results have been subjected to limited review by the statutory auditors of the Company in accordance with| Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 ('the Regulations™) who has issued| an unmodified conclusion on these unaudited financial results. . The unaudited financial results of the company have been prepared in accordance with the Indian Accounting Standards (Ind| AS) as prescribed under Section 133 of the Companies Act, 2013 read with the Companies (Indian Accounting Standards) Rules, 2015, as amended. 3. The company operates in one single reportable business segment and geographical segment i.e. healthcare service in India. 4. The figures of the quarter ended March 31, 2026 are the balancing figure [Showing first 8,000 characters — download PDF for full document]